Key Dates

Related Announcements

PA-20-145 - Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PA-20-145, "Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)."

This PA seeks grant applications focused on rigorous research that addresses the continuum of care for HIV/AIDS (including testing, prevention, treatment, and retention), as well as the range of substance use including substance use disorder that may contribute to HIV risk or impede adherence to HIV care and viral suppression. High risk/high reward exploratory or developmental studies that lack preliminary data or utilize existing data may be more appropriate for this mechanism.

Substance use contributes to HIV risk in multiple ways and can also contribute to inadequate treatment adherence and viremia. Substance use has demonstrated effects that limit the efficacy of prevention and care interventions. Addressing substance use in novel ways may help optimize the effects of evidence-based interventions for HIV prevention and care and these can be considered along the HIV prevention and care continuum from efforts to increase HIV testing among people who use substances through efforts to increase sustained engagement in care and viral suppression among PLWH who use substances.

Areas of Research Interest

Areas of programmatic interest include, but are not limited to:

• Increasing the uptake and frequency of HIV testing and linkage to prevention and care in settings that serve people who use substances (PWUS) at highest substance use risk (e.g., syringe service programs, human service setting for homeless and other populations where high levels of substance use is common)
• Identification of ways in which health disparities add to substance use as a risk for not being reached by HIV prevention and care.
• Development and testing of novel ways to deliver coordinated HIV and substance use services.
• Improvement of HIV treatment outcomes through the development and testing of interventions that will enhance readiness to initiate antiretroviral medications.
• Development and testing of interventions that address stimulant use as part of PrEP initiation.
• Development and testing of implementations of direct service technology-based models as primary modalities for engagement and retention in HIV/AIDS & SUD prevention and treatment in resource limited environments
• Development and testing of interventions that include provider or system-level intervention components to address and reduce barriers to earlier diagnosis, treatment, and continued engagement/retention in HIV and SUD care
• Development and testing of interventions that simultaneously promote ART initiation/adherence and reduce high risk drug use behaviors during periods of non-suppression
• Any of the areas of research interests listed in PA-20-145 with an applicable focus in substance use prevention or treatment

Applications responding to PA-20-145 per this Notice should be consistent with current NIDA HIV Research Priority Areas. See here for more details.

The following sections of PA-20-145 has been added to reflect NIDA's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.279

Section VII. Agency Contacts

Scientific/Research Contact(s)

Minnjuan Flournoy-Floyd, Ph.D.
National Institute on Drug Abuse
Telephone: 301-827-6474
Email: [email protected]

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: [email protected]

Financial/Grants Management Contact(s)
Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: [email protected]

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Minnjuan Flournoy Floyd, Ph.D.
National Institute on Drug Abuse
Telephone: 301-827-6474
Email: [email protected]

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email:[email protected]